Form 4: SAB Biotherapeutics Director Granted 240,000 Stock Options

SAB Biotherapeutics Director David Zaccardelli received an inaugural grant of 240,000 stock options with a $3.74 exercise price, vesting over three years.

Summary

• David Zaccardelli, a Director of SAB Biotherapeutics, Inc. (SABS), was granted 240,000 stock options.
• The transaction date for this grant was January 5, 2026.
• The exercise price for these stock options is $3.74 per share.
• The options represent the inaugural grant to Mr. Zaccardelli as a member of the Board of Directors.
• The shares underlying the option will vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029.
• The options expire on January 5, 2036.
• This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event (stock option grant) to a director. While it introduces potential future dilution, it also aligns the director's interests with shareholders, which is generally viewed as a neutral to slightly positive governance practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The inaugural nature of the grant suggests a commitment to the director's role and future contributions to the company.

Negatives

• The future exercise of these options could lead to dilution for existing shareholders, as 240,000 new shares of common stock may be issued.

Risks

• The value of the stock options is dependent on the future market price of SAB Biotherapeutics' common stock exceeding the exercise price of $3.74.
• The options are subject to a vesting schedule, meaning the director must remain with the company for the specified periods to fully realize the grant.

Future Outlook

The vesting schedule for the stock options over the next three years provides a long-term incentive for the director, aligning their future performance with the company's success. The options' expiration in 2036 indicates a long-term horizon for potential value realization.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages. It is designed to attract and retain talent while motivating long-term value creation.

Comparison to Industry Standards

• The use of stock options as a compensation tool for directors is a standard practice across the biotech industry, similar to companies like Moderna or BioNTech, which frequently use equity grants to incentivize leadership.
• The vesting schedule of three equal annual installments is a common structure for such grants, balancing immediate incentive with long-term commitment, comparable to practices seen in many publicly traded life sciences companies.

Corporate Governance

Related Party Transactions

• The grant of stock options to David Zaccardelli, a Director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of the options, but also benefit from incentivized director performance.
• Employees: No direct impact mentioned, but the use of an equity incentive plan sets a precedent for compensation structures.

Next Steps

• The stock options will vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029.
• David Zaccardelli may exercise the vested options at any time before their expiration on January 5, 2036, assuming the stock price is favorable.

Key Dates

Keywords

SAB Biotherapeutics, SABS, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Incentive Plan, David Zaccardelli